Bowel Cancer Combo Fails to Improve Survival (CME/CE)
(MedPage Today) — Adding the targeted therapy cetuximab (Erbitux) to a standard chemotherapy regimen in advanced colorectal cancer did not extend life, researchers reported.
(MedPage Today) — Adding the targeted therapy cetuximab (Erbitux) to a standard chemotherapy regimen in advanced colorectal cancer did not extend life, researchers reported.
Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
This site complies with the HONcode standard for trustworthy health information: verify here.